Trigger Points of Necroptosis (RIPK1, RIPK3, and MLKL)-Promising Horizon or Blind Alley in Therapy of Colorectal...

Area of Science:

• Oncology
• Cell Death Biology

Background:

• Colorectal cancer (CRC) presents significant mortality due to limited advanced-stage treatment efficacy.
• Necroptosis, a regulated necrotic cell death pathway involving RIPK1, RIPK3, and MLKL, offers a potential alternative for cancer cell death induction.

Purpose of the Study:

• To systematically review the literature on necroptosis's role in colorectal cancer.
• To analyze molecular mechanisms, experimental models, and therapeutic implications of targeting necroptosis in CRC.
• To evaluate the potential of targeting RIPK1, RIPK3, and MLKL as a viable therapeutic strategy for CRC.

Main Methods:

• Systematic literature review of studies on necroptosis in colorectal cancer.
• Critical evaluation of experimental models and molecular mechanisms.
• Analysis of therapeutic implications and clinical outcomes.

Main Results:

• Necroptosis modulation may enhance antitumor immunity and overcome therapeutic resistance in CRC.
• Targeting RIPK1, RIPK3, and MLKL is under investigation for its efficacy in preclinical and clinical settings.
• Evidence suggests necroptosis plays a complex role in CRC progression and treatment response.

Conclusions:

• Targeting necroptosis represents a potential therapeutic avenue for colorectal cancer.
• Further research is needed to determine if targeting RIPK1, RIPK3, and MLKL is a promising strategy or a dead end for CRC therapy.
• Modulating necroptosis could offer new hope for improving survival rates in advanced CRC patients.